FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib treatment. Tepotinib's regular FDA approval in 2024 followed its 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback